Insulin resistance and steatosis in HBV-HCV co-infected patients: Role of PNPLA3 polymorphisms and impact on liver fibrosis progression

Table 3 Distribution of patatin-like phospholipase domain-containing 3 polymorphisms and their relation to steatosis n (%)

PNPLA3	Steatosis no	Steatosis yes	Steatosis score 1	Steatosis score 2-3
Overall
p.148I/I	83 (55)	65 (36)	44%	23%
p.148I/M	62 (41)	82 (46)	49%	40%
p.148M/M	6 (4)	32 (18)b	7%	37%
HBV/HBV-HCV groups
p.148I/I	32 (61)	36 (45.6)	55%	12.5%
p.148I/M	20 (38)	33 (41.8)	42%	37.5%
p.148M/M	1 (1)	10 (12.6)d	3%	50.0%
HCV group
p.148I/I	53 (54)	44 (44)	60%	17%
p.148I/M,	43 (44)	31 (31)	30%	33%
p.148M/M	2 (2)	25 (25)f	10%	50%

^bP = 0.0001;

^dP = 0.0001;

^fP = 0.0001 vs Steatosis no group. PNPLA3: Patatin-like phospholipase domain-containing 3; HBV: Hepatitis B virus; HCV: Hepatitis C virus.